Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001628280-26-012471 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | BLFS | Werner Sean | CTO | A - Grant | — | +24.1K | 50.0K | +93% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | A | A | 24,116 | — | 50,043 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. |